Sarepta Therapeutics(US:SRPT) GlobeNewswire News Roomยท2025-07-18 19:15Core Viewpoint - A lawsuit has been filed against Sarepta Therapeutics, Inc. and its senior executives for potential violations of federal securities laws, particularly concerning the safety claims of its product Elevidys [1][2]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases, with Elevidys being its most significant product aimed at treating Duchenne muscular dystrophy [3]. Allegations and Impact - The lawsuit alleges that Sarepta misrepresented the safety profile of Elevidys, claiming its benefits outweighed risks, while in reality, the treatment has been linked to fatal acute liver failure in some patients [3]. - Following the announcement of patient deaths related to Elevidys, Sarepta's stock experienced significant declines, dropping over 27% on March 18, 2025, and more than 42% on June 16, 2025 [4][5]. Legal Proceedings - Investors have until August 25, 2025, to seek appointment as lead plaintiffs in the case, which is currently pending in the U.S. District Court for the Southern District of New York [2].